Category Archives: Physiology

Physiology

Meet the queen in the north: Yvonne Ejim continues to reign over – Bulletin

Yvonne Ejim is a force to be reckoned with, in and out of the country.

The 6-foot-1-inch forward has made a place for herself on the Gonzaga womens basketball team as a valuable addition to the team.

Doubling as a member of Canadas national team, the GU sophomore from Calgary, Alberta, was named to the West Coast Conference (WCC) All-Tournament Team, seeing action in multiple international tournaments.

It all started when Ejim was 7 years old. Her original exposure to basketball came from her family, but the Steve Nash camp she attended is where she found her passion.

From there, her natural abilities never went unnoticed. Ejim said coaches and parents would make suggestions as to where she could go play in close proximity to her mom, eventually snowballing into playing on the Canadian national team and at GU.

In eighth grade, Ejim was invited to a Team Canada camp. Ejim recounted how they had to make a different slideshow for her to lay out what her time on the team would be like, as she was the youngest by at least a year. Although she didnt make it, the exposure to that environment sparked that interest to go far in basketball.

Ejim continued to play volleyball and track throughout junior high and high school before committing to basketball for the abundance of opportunities presented to her.

I kept going into basketball because I knew this was the thing I wanted to do, Ejim said.

That decision to stick with basketball paid off. She made Team Canada during ninth grade and played with the team through 11th grade.

It was nerve racking, Ejim said. The first time I got that email with the invitation to the national team, I was shocked but really proud of myself for accomplishing that. That was the wow moment for me. Its the national team, its my country, and I want to continue pushing myself with [the team].

Ejim has traveled the world with Team Canada. Her first international tournament was in Argentina, and the lack of a major time difference made the adjustment to playing internationally easier. However, her favorite place has been Bangkok, Thailand, where she played three summers ago.

With Team Canada, we have to keep in mind that we are representing more than ourselves and our families, were representing our country, Ejim said. We take that pride that we have with us wherever we go to show people in other countries what Canada is about.

At GU, Ejim has made a place for herself both academically and athletically.

Studying human physiology, Ejim is just as dedicated to her career goals as she is to her athletic ones. With her natural passion for and abilities in math and science, human physiology felt like the best major to pursue to help her reach her goal of becoming a doctor.

She cited a need to give back to those in the medical field for doing so much as her motivator for pursuing a career as a doctor. Ejim is keeping an open mind for the kind of medical science she wants to pursue, but knows she will end up in the medical field.

On the court, Ejim has made herself indispensable for both her accomplishments and her addition to team morale.

She has the ability to challenge the defense with her ball skills and the way she can guard any position and any player out there, said Head Coach Lisa Fortier. We are also in a time in our world where there are a lot of different opinions on many polarizing issues. Yvonne has a strong yet very thoughtful voice, and has been a leader in our discussions since the minute she stepped on campus.

By incorporating what shes learned from playing internationally, Ejim has taken her game to the next level.

With each countrys team bringing a different set of skills, Ejim has learned how to adapt to different styles of playing and incorporate them into her own skill set.

Playing against national teams with a varying range of skillsets from Mali to Japan has taught her a lot about adjusting to respond to the other teams strengths.

I get all of these different types of players from all of these different countries that bring a different style of basketball to the court, which I really like learning to play around, Ejim said.

As a part of Team Canada, Ejim has played against Japan, Mali, Argentina, Czech Republic, Russia, USA and China, among other countries. Her favorite international team to play is France, where they are all playing professionally.

Playing against them defense wise, seeing how they move and stuff like that, Im able to replicate that into how I move offensively and use that to get better at guarding that style, Ejim said.

While COVID-19 has complicated playing internationally, Canadas bubble strategy made it easy and safe to handle the pandemic while traveling abroad. While they didnt have to wear a mask on the court, everywhere beside the court required a mask.

This season, Ejim is excited to play with a different group of girls and get back onto the court.

Ive had a lot of good experiences traveling and meeting new people because of basketball, Ejim said. That kind of stuff makes me fall in love with the game even more.

Her abilities are being noticed more and more. Racking up an impressive awards list, Ejim won Miss Basketball Alberta her junior year of high school. The award was given to the best female athlete in the province.

Last year, she was named the WCC Freshman of the Week after averaging 8.5 points per game on the road at Santa Clara and San Francisco. She was also named to the WCC All-Tournament Team.

In the future, she wants to play professionally overseas, in the WNBA and to be an Olympian.

Yvonne is our teams energizer bunny, said teammate Cierra Walker. She brings energy and competitiveness everyday. [She] can outrun anyone in transition and defend both posts and guards, and works everyday to not just make herself better but also her teammates.

With her competitive spirit and dedication to her goals, Ejim is a name to look out for in the basketball world.

Link:
Meet the queen in the north: Yvonne Ejim continues to reign over - Bulletin

Physiology

Do you recognize this mystery plant? – Bluffton Today

John Nelson| For Bluffton Today/Jasper County Sun Times

Winter is still a long way off, but the leaves have been falling for several weeks now. Wont be long before sweaters and jackets will be part of the morning routine, along with a steaming bowl of oatmeal. Butter and brown sugar, please.

Autumn and the resultant winter seasons offer plenty of lessons from the world of botany. In general, plants respond to quite a number of environmental signalsthroughout the year.

During autumn, its the accumulated change of day length that has many effects of plants. And of course, it's cooling down, which is important in this way, too. Most plants have already begun a sort of slide into a quiescent period;not exactly hibernation, but similar. There are various ways of seeing these effects exhibited by the plants around us.

For example, many woody species (trees and shrubs) are deciduous everybody knows this and they lose all their leaves regularly. Evergreen species such as our Southern magnolia and American holly, of course, do not fall into this plan.

Botanists like to tell us that late in the growing season, the physiology of the leaves of deciduous species is much changed. Their leaves are, in a sense, dispensable, and dont need to be around any longer than one growing season.

Its sort of sad to see the leaves fizzle out in a colorful last fling and go away, but after they fall, there is something else for botanists to enjoy: twigs. By the way, even evergreentrees eventually lose their leaves, a process lasting two or more seasons.

This weeks mystery plant is a native species, easily familiar to Southerners, as it can be found commonly from Virginia to Oklahoma, then down to northern Florida. It grows in a variety of habitats, including floodplains and low woods, but is perhaps more well-known on high-ground sites, in forests, rocky places, roadsides and even in fields.

This is usually a small tree, but it is potentially quite large (the national champion is more than 100 feettall). They make good street trees, too.

The leaves are rather football-shaped, up to about 2 incheslong or so, with finely serrated margins. Small flowers, not much to look at, appear early in the spring. There will be female and male flowers on the same tree. Ripe fruits are flat and wafer-like, easily able to flutter around in the breeze, enabling dispersal.

The remarkable twigs, during the growing season, produce conspicuous flat bands or wingsof corky, bark-like material. The wings are not always produced to the same degree on every twig of a given tree, so there is much variability in the expression of these wings. The most extreme exhibitions of the wings are on young trees, or on sprouts from stumps.

Why would a plant go to the trouble of making such wings? We don't know. These wings have no known functional value for the plant, so there's an additional mystery. Questions beginning with the word "why" are often unanswerable, especially in the world of nature.

John Nelson is retired curator of the A.C. Moore Herbarium at the University of South Carolina. As a public service, the herbarium offers free plant identifications. For more information, go to http://www.herbarium.org or email johnbnelson@sc.rr.com.

Answer: Winged elm,Ulmus alata

Here is the original post:
Do you recognize this mystery plant? - Bluffton Today

Physiology

USask physical therapy graduate inspired by family – News – University of Saskatchewan – USask News

I knew that (diagnosis) really affected her both emotionally and with the overall quality of life, said Yutuc. My biggest motivation was that I could help people in the same population.

He is set to graduate with a Master of Physical Therapy (MPT) degree from the University of Saskatchewan (USask) at 2021 Fall Convocation on November 10.

By pursuing a degree in physical therapy at USasks School of Rehabilitation Science, Yutuc is also following in the footsteps of his parents, both of whom are in the medical field.

Yutuc became interested in physical therapy while earning his bachelors degree in physiology and pharmacology at USask. He looked into the ways rehabilitation could help individuals with Parkinsons. A career in physical therapy offered the chance to make a positive difference in this area. Yutuc chose USask for his masters program because of the schools research emphasis as well as the inclusive environment.

The thing that got my attention was their focus on research, along with developing the profession and furthering it through evidence-based practice, said Yutuc, noting the schools promotion of health equity and inclusiveness was also a factor. As a minority student, I really wanted to be part of a school that advocated for that. Those are some of the same values that are also important to me.

Health inequity was something he saw during his clinical experiences in urban and rural locations.

When talking to different patients about their progress and experience through the medical system, I found that its harder for people within minority groups to access health care or resources compared to non-minority groups, said Yutuc.

While at the school, Yutuc has been a leader among his peers and an advocate for physical therapy. He served as a representative on both the Physical Therapy Students Society and the MPT admissions committee, helped organize multiple mini-interviews (part of the admissions process until recently), and promoted both the school and the profession to undergraduate students across the university. In addition, Yutuc has helped create connections and community among his classmates during the pandemic.

I was one of the peer leaders for first year students, in a time when the early days of the pandemic kept students from gathering in-person, said Yutuc. The first few months I was able to help organize community events where they could see each other and help each other through schooling, too.

The pandemic has impacted learning for all USask students, including those in physical therapy. Yutuc credits the School of Rehabilitation Science for the ability to shift learning and continue to provide educational opportunities during the pandemic.

The school was really good in being able to transition and adapt to the current (public health) guidelines. Thankfully we were able to go into a hybrid system where we were doing classes online. They gave us the opportunity to do our labs and our clinical skills in person as well, said Yutuc.

He was grateful for the resources instructors and faculty created for Yutuc and his classmates to use at home, acknowledging the extra work faculty put in to provide student resources.

Yutuc is optimistic about his chosen profession and sees multiple possibilities for his career path. He participated in a research project on Parkinsons disease with Dr. Sarah Donkers (PhD), an assistant professor in the school, and can see a future in research.

In terms of my long-term goals, I definitely want to dig into academia and research, he said. Research has bene one of my biggest interests, but also teaching. One of my main goals is to help advocate for the profession itself.

This fall, 926 students are expected to graduate from USask with 939 degrees, diplomas and certificates. These graduates join a century-old community of close to 165,000 alumni worldwide whose contributions are helping to shape our world. Due to the pandemic, in-person ceremonies will not be held. Instead, there are a variety of opportunities to celebrate. Learn more about the celebrations at students.usask.ca/usaskclassof2021.

See the article here:
USask physical therapy graduate inspired by family - News - University of Saskatchewan - USask News

Physiology

Study shows aberrant changes over time in the brains of people with bipolar disorder – News-Medical.Net

Bipolar disorder (BD) is a debilitating psychiatric disorder characterized by fluctuating periods of depression and mania. Researchers have long suspected that BD may be accompanied by abnormal structural and functional changes in the brain. Small cross-sectional brain imaging studies of people with BD have shown hints at those changes, but the ability to interpret data collected at a single timepoint is limited. Now, a multi-center longitudinal study shows aberrant changes over time in the brains of people with BD. Some changes were specifically associated with more episodes of mania.

The report appears in Biological Psychiatry, published by Elsevier. The study involved a large international multi-center team of more than 70 researchers from the ENIGMA Bipolar Disorder Working Group.

The ENIGMA Bipolar Disorder Working Group report illustrates the power of large-scale multi-center collaboration. Longitudinal neuroimaging studies are extremely challenging to conduct. Here, by combining data from 14 sites, we get one of the clearest pictures we have of the neurotoxic impact of bipolar disorder, particularly manic episodes."

John Krystal, MD, Editor of Biological Psychiatry

The researchers gathered magnetic resonance imaging (MRI) and detailed clinical data from 307 people with BD and from 925 healthy controls (HC) from 14 clinical sites worldwide. Participants were assessed at two timepoints, ranging from six months to nine years apart.

The most striking finding was that the cortex, the brain's outermost layer, thinned over time to a greater extent in people who experienced more manic episodes. Those who did not have mania showed no cortical thinning or even cortical thickening. The changes were most evident in the prefrontal cortex (PFC), an area associated with executive control and emotion regulation.

"The fact that cortical thinning in patients related to manic episodes stresses the importance of treatment to prevent mood episodes and is important information for psychiatrists," said senior author Mikael Landn, MD, PhD, Professor and Chief Physician at the Institute of Neuroscience and Physiology, University of Gothenburg, Sweden. "Researchers should focus on better understanding the progressive mechanisms at play in bipolar disorder to ultimately improve treatment options."

Compared to HC, people with BD showed a faster enlargement in the brain's ventricles, cavities within the brain that contain cerebrospinal fluid. In cortical areas outside the PFC, BD participants actually showed slower thinning than HC participants.

Lead author Christoph Ab, PhD, Assistant Professor, Karolinska Institutet, Sweden, said: "The abnormal ventricle enlargements and importantly the associations between cortical thinning and manic symptoms indicate that bipolar disorder may in fact be a neuroprogressive disorder, which could explain the worsening of bipolar symptoms in some patients."

One possibility to explain why BD patients may have slower thinning of the cortex compared to HC is that lithium, a medication used to treat BD, is known to have neuroprotective effects and could bolster cortical thickness. Regardless, the study provides new clues about the structural effects of BD on the brain over time.

Source:

Journal reference:

Ab, C., et al. (2021) Longitudinal structural brain changes in bipolar disorder: A multicenter neuroimaging study of 1,232 individuals by the ENIGMA Bipolar Disorder Working Group. Biological Psychiatry. doi.org/10.1016/j.biopsych.2021.09.008.

See the rest here:
Study shows aberrant changes over time in the brains of people with bipolar disorder - News-Medical.Net

Physiology

RET Alterations in Advanced NSCLC – OncLive

Stephen Liu, MD: RET does have a normal role in physiology. RET stands for rearranged during transfection, and it encodes a transmembrane receptor tyrosine kinase, which is important for the development of neurons. Particularly the enteric nervous system development of a lot of nerve signaling pathways. Its primary role in normal physiology is in the development of the gut, the enteric system, and the kidney.Mark A. Socinski, MD: RET alterations have been known since the 1980s. Ive personally been involved with lung cancer programs that have tested for RET alterations for a decade or so. The frustration was that we didnt have good selective RET inhibitors prior to the recent approval of pralsetinib and selpercatinib, which are highly active RET drugs. RET fusions, like ALK fusions, ROS1 fusions, and NTRK fusions, become oncogenic drivers. They turn on the growth pathway, survival pathways, and give the cancerous cells an advantage over the normal cell population, leading to uncontrolled proliferation, which is one of the hallmarks of cancer.

Ben Levy, MD: We now have data that shows RET has multiple fusion partners. In fact, theres more than 40 unique fusion partners for RET, when we talk about RET fusions in lung cancer, and particularly other solid tumor cancers, like thyroid. Most importantly, the most common RET fusion partner is the KIF5B fusion partner. This is the one that we saw most commonly in both the selpercatinib data and the pralsetinib data, but there are other fusions that have been seen. CCDC6 and NCOA4 are also fusion partners that can be identified. Clearly, its important to make sure that you have a fusion. When youre looking at a next-generation sequencing report, its not a RET mutation that predicts sensitivity to these new FDA-approved therapies, its the fusion. So yes, you can look at the fusion partner and see what it is, but I think were still trying to learn whether the type of fusion partner predicts efficacy to selpercatinib and pralsetinib. I think we know that the RET fusion partner, KIF5B, does predict efficacy to both pralsetinib and selpercatinib. But fusions arent mutations. When youre getting a next-generation sequencing report, make sure its the fusion. And then yes, of course you can look at the partner. But did they tell a different story? Thats important to understand.

Transcript edited for clarity.

View post:
RET Alterations in Advanced NSCLC - OncLive

Physiology

NFF: Coaching course will take us back to 1994 era, says Okoson – Punch Newspapers

Published 30 October 2021

Robinson Okoson, the Deputy Director technical and Head Psychology unit of the Nigeria Football Federation (NFF) on Friday said coaching courses will help to take Nigeria back the golden era of 1994.

Okoson told journalists at the end of a five-day coaching course that the training course was targeted at the train the trainers.

He said the name of the course entitled Elite Instructor Coaches Course, will take Nigeria back to the golden era where a lot of football physiology was found in every club and players will play the same pattern.

The News Agency of Nigeria reports that the coaching course was organised by the NFF in collaboration with the Confederation of African Football (CAF).

Okoson said 32 coaches participated in the course, saying that coaches were selected randomly from all the 36 states, including Abuja.

We came up with this programme that will enhance the quality of our coaches which will help us on the quality of play in the league and help all our players generally.

The training covers their physiology, tastics and technical aspects of the game, he said.

He said in the nearest future, Nigeria will start to reap the results of the training.

These coaches trained, will go to grassroots to impart what they have learnt.

In the nearest future let say six to ten years we will be reaping the results of what we just did in terms of bringing out players across the country in a physiology way, he said.

He said they will also organise the CAF A and CAF B license course.

We are also going to do another programme where we will also bring another set of Coaches.

We have a lot of other coaches in Nigeria we want to put a stop to all these academies that are just springing up here and there, Academies that dont really have access to the level of coaching we have, he said.

NAN reports that the five-day Elites Instructor Coaches Course which started on Monday ended on Friday (NAN)

Visit link:
NFF: Coaching course will take us back to 1994 era, says Okoson - Punch Newspapers

Physiology

Mot Hennessy pledges to reduce its carbon footprint and invest in sustainability – decanter.com

Mot Hennessy, the wine and spirits division of leading luxury goods group Mot Hennessy Louis Vuitton (LVMH), has issued a pledge to reduce its carbon footprint by adopting the 1.5C target, as stipulated under the Paris Agreement and confirmed by the Science Based Targets initiative partnership (SBTi).

As part of the pledge, Mot Hennessy is committed to reduce its greenhouse gas emissions by 50% in absolute value by 2030 (compared to 2019 figures) by focusing on four core areas: reduce its raw materials carbon impact, develop eco-conscious packaging, leverage renewable energy, and promote low-carbon transportation.

We believe we have an important responsibility alongside the wines and spirits industry to significantly reduce our carbon footprint throughout the value chain, while developing biodiversity in our regions, said Mot Hennessy CEO, Philippe Schaus. We have set ambitious goals that we are committed to following regularly and integrating into Mot Hennessys overall strategy.

The announcement follows a series of sustainable viticulture initiatives released as part of Mot Hennessys Living Soils Living Together programme. Last week, the business inaugurated its new Robert-Jean de Vog Research Centre near its Mont Aigu winery in Oiry, Champagne. The centre, which cost the group some 20m (17m), is dedicated to advancing knowledge of future environmental and production challenges, tackling climate change, and to developing sustainable winemaking practices.

Faced with the two main environmental challenges of climate change and the loss of biodiversity, Mot Hennessy has structured all of its actions in its Living Soils Living Together programme, our social and environmental commitment, Mot Hennessy chief sustainability officer, Sandrine Sommers told Decanter. We have set ourselves ambitious goals for 2030 To support this we need research, innovations and new solutions and our new [centre] is crucial to meet the challenges of viticulture of tomorrow.

Conceived by architect Giovanni Pace, the new research centre covers an area of 4,000m2 and the building itself is designed to showcase Mot Hennessys commitment to sustainability. It is made from materials that grant natural insulation, which helps reduce energy consumption, and is embedded in a gently sloping earthen embankment to ensure it blends graciously with the surrounding landscape.

Its research efforts will focus on four key areas: a microbiology and biotechnology hub will be dedicated to better understand the impact of microorganisms on vineyards and on the fermentation process, while a further hub will focus on plant physiology, to mitigate the impact of climate change on vines and grapes and tackle the challenges induced by warming temperatures. The plant physiology team will benefit from innovative infrastructures such as climate chambers, which are capable of simulating climate changes in Mot Hennessy vineyards across the globe.

A process engineering hub will be destined to analyse the winemaking process, from pressing to bottling, with the aim to optimise it and to promote recyclability. Lastly, the sensory analysis and formulation hub will focus on studying the organoleptic profile of Mot Hennessy products throughout the different stages of the manufacturing process to maximise wine quality.

The research centre will be a hub for sharing knowledge both between [our] houses and with public sector researchers and will also embrace collaboration with other external structures, said Schaus. Indeed, over 10 partners will collaborate with the centre, including the Comit Interprofessionnel du Vin de Champagne (CIVC), the University of Reims Champagne Ardennes, and Frances National Research Institute for Agriculture, Food and Environment (INRAE de Colmar).

The new centre is named after Mot Hennessy former president and innovator, Robert-Jean de Vog, who contributed to the creation of the CIVC in 1941. Robert-Jean de Vog always thought a quarter-hour ahead, Schaus said. A great figure in the world of wine, he left an indelible impression on his era with his innovative spirit and activities with Maison Mot & Chandon in France and around the world.

See the article here:
Mot Hennessy pledges to reduce its carbon footprint and invest in sustainability - decanter.com

Physiology

Ipsen Appoints Stewart Campbell Executive Vice President and President of North America – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Stewart Campbell as Executive Vice President and President of North America, effective immediately. Based in Cambridge, he will lead the business in the US and Canada, continuing to drive Ipsens positive impact for patients. He will report directly to David Loew, CEO, Ipsen and serve on the Executive Leadership Team (ELT).

Stewart brings extensive experience in the pharmaceutical industry which will be instrumental in accelerating Ipsens growth in North America as we continue to strengthen our global footprint and deliver our new group strategy, Focus. Together. For patients and society. We are delighted to welcome him to the ELT, and we look forward to working closely with him, said David Loew, CEO, Ipsen.

Im excited to be appointed as EVP and President of North America at this key moment for Ipsen, said Stewart Campbell. Ive been impressed by the dedication that Ive seen from all of Ipsen as we work together to improve the lives of patients and their families. I am looking forward to helping write the next chapter of our story in North America.

Stewart joined Ipsen as Senior Vice President and Franchise Head of Oncology earlier in 2021 from Roche/Genentech where he spent more than 14 years and was responsible for the lifecycle management of some of Roches oncology blockbusters, including both commercial and clinical development globally. Through a career of more than 20 years in the pharmaceutical industry, Stewart has gained deep experience leading country and global commercial functions in Oncology and Specialty Care markets, including in Canada, Switzerland and the US.

Stewart is a graduate of Concordia University in Montreal, Canada, where he received his B.S. in physiology with a minor in physics. He received an MBA in corporate finance from Queens University in Kingston, Canada and an additional MBA in business strategy from the Johnson School of Management at Cornell University in Ithaca, New York.

Ipsen North America

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. Its resources, investment and energy center on discovering, developing and commercializing medicines in three key therapeutic areas Oncology, Rare Disease and Neuroscience. The Company is dedicated to providing hope for patients whose lives are challenged by unmet medical needs. Ipsens North American operations are located in Cambridge, Massachusetts, one of the Companys three global hubs. For more information, please visit http://www.ipsenus.com.

Forward-looking statements

The forward-looking statements, objectives and targets contained herein are based on Ipsens management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsens future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words believes, anticipates and expects and similar expressions are intended to identify forward-looking statements, including Ipsens expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsens patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsens activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsens partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsens business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsens business is subject to the risk factors outlined in its registration documents filed with the French Autorit des Marchs Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsens 2020 Universal Registration Document, available on ipsen.com.

Read the original:
Ipsen Appoints Stewart Campbell Executive Vice President and President of North America - Business Wire

Physiology

Stress and the gut: pathophysiology, clinical consequences …

Stress, which is defined as an acute threat to homeostasis, shows both short- and long-term effects on the functions of the gastrointestinal tract. Exposure to stress results in alterations of the brain-gut interactions ("brain-gut axis") ultimately leading to the development of a broad array of gastrointestinal disorders including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and other functional gastrointestinal diseases, food antigen-related adverse responses, peptic ulcer and gastroesophageal reflux disease (GERD). The major effects of stress on gut physiology include: 1) alterations in gastrointestinal motility; 2) increase in visceral perception; 3) changes in gastrointestinal secretion; 4) increase in intestinal permeability; 5) negative effects on regenerative capacity of gastrointestinal mucosa and mucosal blood flow; and 6) negative effects on intestinal microbiota. Mast cells (MC) are important effectors of brain-gut axis that translate the stress signals into the release of a wide range of neurotransmitters and proinflammatory cytokines, which may profoundly affect the gastrointestinal physiology. IBS represents the most important gastrointestinal disorder in humans, and is characterized by chronic or recurrent pain associated with altered bowel motility. The diagnostic testing for IBS patients include routine blood tests, stool tests, celiac disease serology, abdominal sonography, breath testing to rule out carbohydrate (lactose, fructose, etc.) intolerance and small intestinal bacterial overgrowth. Colonoscopy is recommended if alarming symptoms are present or to obtain colonic biopsies especially in patients with diarrhoea predominant IBS. The management of IBS is based on a multifactorial approach and includes pharmacotherapy targeted against the predominant symptom, behavioural and psychological treatment, dietary alterations, education, reassurance and effective patient-physician relationship. When evaluating for the stress-induced condition in the upper GI tract, the diagnostic testing includes mainly blood tests and gastroscopy to rule out GERD and peptic ulcer disease. The therapy for these conditions is mainly based on the inhibition of gastric acid by proton pump inhibitors and eradication of Helicobacter pylori-infection. Additionally, melatonin an important mediator of brain gut axis has been shown to exhibit important protective effects against stress-induced lesions in the gastrointestinal tract. Finally, probiotics may profoundly affect the brain-gut interactions ("microbiome-gut-brain axis") and attenuate the development of stress-induced disorders in both the upper and lower gastrointestinal tract. Further studies on the brain-gut axis are needed to open new therapeutic avenues in the future.

Read more:
Stress and the gut: pathophysiology, clinical consequences ...

Physiology

New faculty profile: Joe Pierre studies diet, gut physiology, and the microbiome in health and disease eCALS – wisc.edu

Joe Pierre joined the UWMadison faculty in October 2021 as an assistant professor in the Department on Nutritional Sciences. Funding for this nutrition-focused position comes from the Dairy Innovation Hub, which has supported 11 faculty positions so far at UWMadison, UWPlatteville and UWRiver Falls.

What is your hometown? Where did you grow up?I grew up in Green Bay and Door County, Wisconsin, a little over 2 hours northeast of Madison.

What is your educational/professional background, including your previous position?I attended UWMadison as an undergraduate (BS in natural science) where I was a student athlete in track and cross country from 2005-2008. I then completed a Ph.D. in nutritional sciences through the IGPNS program at UW. Following graduation, my postdoctoral fellowship training was in gastroenterology, hepatology, and nutrition at the University of Chicago. Prior to joining the UW faculty, I was most recently an assistant professor of pediatrics, microbiology, immunology, and biochemistry at the University of Tennessee Health Science Center.

How did you get into your field of research?The gastrointestinal tract serves as the largest external surface of the body and is tasked with digesting and absorbing nutrients, mediating cohabitation with trillions of microorganisms, and acting at the largest endocrine and immune organ. As I learned more about the many important roles the gut plays in human health, I became more fascinated by how diet and resident microbial communities fundamentally shape metabolic and immune responses in the gut and throughout the body. My fellowship training was focused on the tools and concepts for studying the gut microbiome and host metabolites. Putting all these experiences together, it was a natural next step to bring these experiences and interests back to the field of nutritional sciences.

What are the main goals of your current research program?My research program has been centered around understanding the roles of diet, gut physiology, and the microbiome in health and disease. We have existing NIH funding examining the role of diet and bariatric surgery on breast cancer outcomes, the role of the microbiome/mycobiome in inflammatory bowel disease, and how extraintestinal microbial communities (in circulation) shape cardiovascular events. At UW, my program will continue to utilize diverse experimental tools (bariatric surgery, parenteral nutrition, gnotobiotics, microbial sequencing, and enteroids) to gain deeper insights into nutritionally relevant areas emphasizing dairy components in the context of disease treatment, prevention and optimizing human health.

What attracted you to UWMadison? UWMadison is a research powerhouse with thousands of talented faculty colleagues, laboratory resources, core facilities, along with thoughtful and hardworking students and trainees to interact with. If there is a scientific hypothesis worth testing, you can successfully pursue it at the UW.

What was your first visit to campus like?I believe my first visit to campus was as a child (my brother was an engineering student), but I remember touring campus as a high school track recruit with then head coach, Ed Nuttycombe. The impression and beauty of this campus never gets old.

Whats one thing you hope students who take a class with you will come away with?I hope my students are inspired by the materials and concepts and go on to pursue lifelong curiosity outside of the classroom that enriches their lives and professional careers.

Do you share your expertise and experiences with the public through social media? If so, which channels do you use?I am an infrequent user of social media but maintain a Twitter and LinkedIn account.

Do you feel your work relates in any way to the Wisconsin Idea? If so, please describe how.Absolutely. The pursuit of basic and translational research knowledge especially in metabolism, nutrition, and health benefits the residents of Wisconsin and beyond. More specifically, a key emphasis of my program is gaining deeper insights into the use of dairy components and products in human health and nutrition. Milk is a fundamentally important source of nutrition in mammalian biology. Dairy products contain complete protein, hundreds of bioactive peptides and enzymes, and unique lipids that have been key assets to human agriculture and success for millennia. Beyond human health, dairy is economically important to Wisconsin and many populations around the globe.

Whats something interesting about your area of expertise you can share that will make us sound smarter at parties?It may sound clich, but we really are a product of what we eat. Beyond energy, our diets begin an enormously complex cascade of metabolites, microbial adaptation and selection, and host cell and organ system responses that are fascinating and interconnected in many ways that were still trying to understand. Appreciating the catalyzing role of diet synergizes with the biochemical, genetic, environmental, lifestyle and microbiological academic pursuits in understanding human biology.

What are your hobbies and other interests?As a father of several young kids, I spend a lot of time at home, with the occasional camping trip or golf outing.

Read the original post:
New faculty profile: Joe Pierre studies diet, gut physiology, and the microbiome in health and disease eCALS - wisc.edu